The global GLP-1 revolution in obesity medicine, driven by Wegovy, Mounjaro, and their accelerating successors, has largely been a story written in the United States, Denmark, and the European Union. That story now has a new chapter, and it begins in Seoul. In October 2026, Hanmi Pharmaceutical became the first Korean company to win regulatory approval for a domestically developed GLP-1 receptor agonist for obesity. The drug is called Eppe, its active ingredient is efpeglenat